Imperative Care Raises $100M in Convertible Funding to Expand Stroke Treatment Platform

There’s a moment in stroke care where time stops being measured in minutes and starts being measured in outcomes. That space between intervention and irreversible damage is where Imperative Care, Inc. decided to build an entire company. Not a product. Not a pitch deck. A full-stack assault on one of medicine’s most unforgiving clocks.

Now they just pulled in $100M in convertible note financing, and the room got a little quieter. The kind of quiet that happens when serious operators make another calculated move. Elevage Medical Technologies and Perceptive Advisors stepped in as new co-leads, alongside Catalio Capital Management, LP, with Longaeva Partners LP and Brown Advisory joining the table, while Ally Bridge Group and Bain Capital Life Sciences doubled down. Capital is loud. Conviction is louder.

Fred Khosravi and Yi Yang didn’t stumble into this. Fred Khosravi has been stacking medtech wins for 30+ years, building and exiting companies like it’s muscle memory. Yi Yang has been engineering in the trenches long enough to know that precision is not optional when you are navigating the human vascular system. And the late L. Nelson Hopkins, III, M.D. helped define the very field they are now pushing forward. This is not a founding team. This is a lineage.

The product story reads like physics meeting urgency. The Zoom Stroke System is not just another catheter lineup, it is a coordinated system designed to move fast and think faster. In clinical data, they are hitting mTICI ≥2B reperfusion in over 80% of cases, with median times clocking in at 19 minutes. That is not incremental. That is the difference between recovery and a very different life.

Then you layer in Symphony for pulmonary embolism, Prodigy across vascular, Kandu Health extending care beyond the procedure, and Telos Health pushing toward robotic intervention and remote access. Four fronts, one mission. Treat the event, manage the aftermath, and start bending access curves in places that have been historically underserved.

Over 78,000 procedures in, this is no longer theory. It is repetition. And repetition is where great companies separate from interesting ones. The kind of repetition that investors don’t just notice, they price in.

The $100M goes where it should. Commercial scale, deeper clinical evidence, and continued buildout of next-gen platforms, especially robotics. Evan Melrose, M.D., MBA joining the board adds another layer of operator oversight with investor discipline baked in.

The takeaway is simple, but not easy. Imperative Care did not raise on vision alone. They raised on data, iteration, and a refusal to treat stroke as a single moment instead of a continuum. In a market pushing toward $90B+ over the next decade, they are not chasing the wave. They are engineering how it breaks.